Executive Summary

1. 1
SMART CONTACT LENSES
and STYLISH GLASSES
Patients and Consumers
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and iOptik is a registered trademark, of Innovega Inc.
Engineered by Innovega Inc.

2. 2
FORWARD-LOOKING STATEMENTS
This presentation contains forward-looking statements and information relating to, among
other things, Innovega Inc, its business plan and strategy, and its industry.
These statements reflect management’s current views with respect to future events based on
information currently available and are subject to risks and uncertainties that could cause the
company’s actual results to differ materially.
Investors are cautioned not to place undue reliance on these forward-looking statements as
they are meant for illustrative purposes and they do not represent guarantees of future results,
levels of activity, performance, or achievements, all of which guarantees cannot be made.
Moreover, no person or entity assumes responsibility for the accuracy and completeness of
these forward-looking statements, and no persons or entities are under any duty to update any
such statements to conform them to actual results.
2

3. 3
TRANSFORMATIVE EYEWEAR SYSTEM
• Transformative for
• Partially-sighted patients who have lost
their lifestyle
• An Industry whose growth has stalled
and is in need of innovation
• Normal, Stylish Glasses for medical,
consumer and industrial applications
• 30 domestic plus additional international
patents plus trade-secrets
• The company will initially license its technology
into the $74B global vision care market
• Advisor teams include senior executives
from Microsoft, Sony and Bausch + Lomb
3

4. 4
EMACULA™ SYSTEM
UNPRECEDENTED ASSISTANCE FOR 15 M
VISUALLY IMPAIRED PATIENTS
• Problem: Patients with visual impairment require
magnification to see what a sighted person sees
• The magnification required by patient is too great for
normal prescription eyeglasses or contact lenses
• Innovega Cameral on Glasses Solution: Camera mounted
on glasses captures, magnifies, and enhances the
patient’s world to instantly deliver functional vision
• Patient wears Innovega smart contact lens and glasses
that instantly deliver magnified, enhanced and
panoramic sight from lightweight, stylish eyewear system
4

5. 55
SMART PERSONALIZED CONTACT LENSES
PROPRIETARY NANO-TECHNOLOGY POLARIZERS
Outer Filter & Lens
Capturing Real-World View
Contact Lens
Will include Personal Prescription
Center Filter & Lenslet
Capturing Digital Media
5

6. 6
MANY SMART GLASSES CONFIGURATIONS
AR Panoramic
AR Mobile
VR Lite
VR Immersive

7. 7
INNOVEGA TEAM
Steve Willey: Co-Founder, CEO & Director — Passion for commercializing
game-changing technologies (Co-founder and president, MicroVision
(NASDAQ: MVIS); “turn-around” CEO of AirIQ Inc (TSXV:IQ) ; multiple
business and general management of start-ups that were later acquired by
Fortune 100 companies.
Jay Marsh: VP Engineering — Former VP Engineering with APRI, and more
than 25 years developing systems that achieved unprecedented
performance; leadership of multidisciplinary engineering teams dedicated
to delivering complex electro / optical / mechanical systems
Dr. Jerome A. Legerton: Co-Founder, Director — Successful career in
contact lens development and commercialization; 56 issued U.S. patents,
co-inventor of Paragon CRT® contact lenses, the market leader for
overnight corneal reshaping. Co-founder and former CTO and EVP of
SynergEyes, Inc., the world leader in hybrid contact lenses.
7

8. 8
LARGE PATIENT AND CONSUMER MARKETS
8
https://www.prnewswire.com/news-
releases/global-74-bn-vision-care-market-to-2024-
300817009.html
https://www.grandviewresearch.com/industry-
analysis/contact-lenses-market
https://www.marketwatch.com/press-release/ar-and-vr-smart-
glasses-market-2019-global-size-share-trends-growth-
opportunities-key-players-industry-segments-and-forecast-2023-
2019-02-11
$74B global
Vision Care
market
$11B Global
Contact Lens
market
USD $31B Consumer
Smart Glasses market
(Forecast 2023)

9. 9
INNOVEGA REVENUE MODEL
• License of intellectual property to
eyewear and contact lens
manufacturers, and to distributors
that will sell and market the
combined system
• Multiple revenue streams:
Upfront license fee; future
royalties based on sales or profits;
NRE (Non-recurring engineering)
fees to fund Innovega
collaboration
• Innovega also develops and
fabricates working contact lens
and eyewear prototypes and
limited production runs
• Upfront licenses fees could be seven figures
or more
• Glasses royalties could be a percentage of
price paid by the patient
• Contact lens royalties could be a percentage
of recurring revenue from disposable lenses
• Non-recurring engineering (NRE) fees could
be seven figures or more
9

10. 10
GO-TO-MARKET STRATEGY
CAPITAL-EFFICIENT STRATEGIC PARTNERSHIP MODEL
1. CORE: 15 M VISUALLY IMPAIRED PATIENTS
• Glasses fitted with high magnification camera
• Provide panoramic and magnified world-view
• Meets patient lifestyle demand for “glasses”
2. UPSIDE MARKETS: MASS MARKET CONSUMERS
• Consumers want mobility and glasses style
• Consumers expect big, rich media
• TENCENT is a lead investor / potential partner
10
Today’s Unacceptable Goggles

11. 11
UPSIDE CONSUMER MARKETS
THOSE CONSUMERS WHO WANT OR NEED STYLISH GLASSES
VS.
11

12. 12
WEARERS NEED THESE “10” FEATURES
Comfort
1. Lightweight, balanced (2-3 oz)
2. No Eyestrain or headaches (“solve” vergence-accommodation conflicts!)
3. Integrated Vision Correction (62% of humans require vision correction)
4. Socially Comfortable: Any Style, Normal Glasses
High Performance
5. High-resolution / Eye-limited, Retinal Display (1.2 arc-minute resolution)
6. Panoramic, Unobstructed Field of View (over 100 degrees)
7. Highest Image Quality, High-efficiency screens (ex. OLED)
Many Configurations and Applications
8. VR/AR/MR (today’s and future configurations)
9. Any Image Source (Microdisplay screens, Pico-projectors)
10. Expandable and Extendable (ex. Integrated Eye-tracking, ex. 5g Edge device)
12

13. 13
EMACULATM UNIQUELY DELIVERS ALL “10” FEATURES
Comfort
1. Lightweight, balanced (2-3 oz)
2. No Eyestrain or headaches (“solve” vergence-accommodation conflicts!)
3. Integrated Vision Correction (62% of humans require vision correction)
4. Socially Comfortable: Any Style, Normal Glasses
High Performance
5. High-resolution / Eye-limited, Retinal Display (1.2 arc-minute resolution)
6. Panoramic, Unobstructed Field of View (over 100 degrees)
7. Highest Image Quality, High-efficiency screens (ex. OLED)
Many Configurations and Applications
8. VR/AR/MR (today’s and future configurations)
9. Any Image Source (Microdisplay screens, Pico-projectors)
10. Expandable and Extendable (ex. Integrated Eye-tracking, ex. 5g Edge device)
13

14. 14
PARTNER BUSINESS MODEL - STATUS
• Innovega delivers core technology,
prototypes, applications
• Partners “brand” glasses / lenses
• Multiple revenue streams
• Existing relationships or discussions
with these global companies =>
14

15. 15
KEY INVESTORS, DIRECTORS, AND LEADERSHIP
World’s largest video game
company & world’s largest
social media company
Med-Tech Investment Firm
VC focused on gaming and
social media
Jeff Xiong, FORMER CTO, TENCENT
Shane Kim, INTERIM CEO, GAMESTOP; FORMER VP MSFT XBOX
Jerome Legerton, OD, CO-FOUNDER SynergEyes
Steve Willey, CO-FOUNDER MicroVision
Steve Willey, MBA
CEO
Jerome Legerton, OD
CHIEF CLINICAL OFFICER
Jay Marsh, M Sc EE
VP ENGINEERING
Bill Meyers, PhD
VP CONTACT LENSES
Mark Freeman, PhD
DIRECTOR OPTICS & PHOTONICS
Peter Schuster, CPA
DIRECTOR FINANCE
INVESTORS DIRECTORS
LEADERSHIP TEAM
15

16. 16
BUSINESS, CLINICAL, SCIENTIFIC ADVISORY BOARDS
Phil Molyneux, Consumer Electronics
REGIONAL PRESIDENT DYSON. FORMER PRESIDENT, SONY
ELECTRONICS, INC. N.A.
Avram Miller, Capital Formation
CO-FOUNDER INTEL CAPITAL. FORMER VP, BUSINESS
DEVELOPMENT, INTEL CORP.
Dan Spira, Healthcare
FORMER NORTH AMERICA VP, BAUSCH & LOMB WITH
RESPONSIBILITIES ACROSS EYE HEALTH, SKINCARE AND
AESTHETICS; FORMER VP, JOHNSON & JOHNSON
Jayson Chi, Video Game industry
FORMER PARTNER MCKINSEY GROUP
(GLOBAL LEAD, VIDEO GAMING PRACTICE)
Robert Simmonds, Mobile Carrier
FOUNDER, FORMER CHAIRMAN OF CLEARNET
COMMUNICATIONS. ACQUIRED BY TELUS CORP FOR $6B
Joe Barr, OD, MS
FORMER GLOBAL VP FOR CLINICAL AND MEDICAL AFFAIRS, BAUSCH &
LOMB; EMERITUS PROFESSOR THE OHIO STATE UNIVERSITY
Mark Bullimore, MCOptom, PhD
FORMER FDA OPHTHALMIC DEVICE PANEL MEMBER; FDA EXPERT ON
VISION ASSESSMENT; DEAN MARSHALL B. KETCHUM UNIVERSITY,
COLLEGE OF OPTOMETRY
Richard Lindstrom, MD
FOUNDER AND ATTENDING SURGEON MINNESOTA EYE CONSULTANTS;
ADJUNCT PROFESSOR EMERITUS, UNIVERSITY OF MINNESOTA
DEPARTMENT OF OPHTHALMOLOGY, OPHTHALMOLOGY EXPERT IN
MEDICAL DEVICES AND CORNEAL AND CATARACT SURGERY
Steve Schallhorn, MD
OPHTHALMOLOGY EXPERT IN MEDICAL DEVICES AND CORNEAL AND
CATARACT SURGERY; FORMER DIRECTOR, NAVAL REFRACTIVE SURGERY
CENTER SAN DIEGO
Jim Schwiegerling, PhD
PROFESSOR, UNIVERSITY OF ARIZONA - OPHTHALMOLOGY AND
VISION SCIENCE; OPTICS EXPERT
16

17. 17
STATUS OF EMACULA U.S. FDA PROCESS
• In-person Pre‐submisson FDA meeting has occurred
• Phase II clinical trials underway; Pre-clinical testing underway
• Phase III FDA clinical trial will start upon Phase II trial completion
• Phase III (Part 1)
• 510(k) process for approval of lens material
• 510(k) process is a premarket submission made to FDA
to demonstrate that a non-significant risk device (Class
II) to be marketed is substantially equivalent in safety
and effectiveness to an already FDA cleared Class II
device for the same medical indications.
• Phase III (Part 2)
• FDA De Novo process for approval of the iOptik® display lens
• No previously cleared device for viewing a near eye display
17

18. PROGRESS AND PLANNEDMILESTONES
This slide reflects management’s current views with respect to future events based on information currently available and is subject to risks and uncertainties.
This slide is meant for illustrative purposes and does not represent guarantees of future results, levels of activity, performance, or achievements.
18

19. 19
9,874,765 Dual path contact lens
2014/0138544 MEMS based Eye Tracking, 2
2017/0337706
Low Latency Gaze Tracker
Patterned
Polarizer
8,142,016
Lens-let Molding into Contact Lens
Contact Lens
Component Containing Molding
2016/0216534
Contact Lens with Non-
Permeable Inserts
8,922,898
Wire Grid Polarizer in Lens
8,482,858 Deflection Optics
9,869,884
Contact Lens
2015/0084999 See Through Display
with Pixilation Occlusion, 2
9,251,745 See Through Display
with Pixilation Occlusion, 1
8,441,731 Direct View
Transparent Display
2018/0090052
Large Field of View Head-worn Display
2016/0131910 TFD based display8,922,897 Pixilated Occlusion for TFD
8,520,309 Display and Non
Display Path Foundational Case
8,786,520
Direct View Display in Eyewear
9,040,923 MEMS based Eye Tracking, 1
High Resolution
Transparent Display
Implanted Optical
Device
Camera Eyewear
Methods of Fitting Display Eyewear
SUCCESSFUL PATENT MANAGEMENT
Display
Systems
Eye Tracking
Filters
Filed - Unpublished by USPTO
Application in process
Core (14)
1st Order (7)
2nd Order (5)
8,888,279 Filters with Lenslet
9,348,151 Molded lens with nanofilaments, 1
2015/0205146 Molded lens with nanofilaments, 2

20. 20
SUMMARY
• Experienced team has delivered $6M working systems
• Valuable portfolio of domestic and foreign patents
• Core Market of 15 million Visually Impaired Patients
• Uniquely meets needs of Upside Consumer Markets
• FDA Phase II trials near completion; Final Phase planned
• Strategic partners invested $5.5M - led by Tencent
• Discussions with Operating Partners and Investors
• We welcome your involvement
20